Mark R. Hake

Mark R. Hake

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Amwell Is a High-Priced Telehealth Stock With No Profits

Amwell is another high-priced telehealth stock with no profits. Avoid AMWL stock which trades at 24 times sales with no earnings prospects in the near term.

JFrog Is Still Wildly Overvalued Ahead of Insider Share Lockout Release

JFrog is still ridiculously overvalued ahead of its insider share lockout release. FROG stock is still trading for 29 times 2021 revenue forecasts, which is too high for most value investors.

Overvalued Alteryx Guides for Lower Revenue and Flat Earnings

Alteryx guides for lower revenue and flat earnings, leaving AYX stock overvalued. AYX stock is too high at 177 times earnings given that revenue and earnings are set to fall in Q4.

Nikola Will Likely Keep On Losing Money, Pushing NKLA Stock Lower

Nikola will likely keep on losing money, pushing NKLA stock lower. It is worth over 8 times less based on its negative cash flow.

Inovio Has Little to Show for Its Covid-19 Efforts

Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.